Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowGains from Investment SecuritiesGains from Sales and DivestituresNet Cash FlowNet IncomeNon-cash ItemsOther Working Capital ChangesOther financing activitiesSales of Property, Plant and EquipmentShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Immucell (ICCC) Net Cash Flow (2016 - 2025)

Historic Net Cash Flow for Immucell (ICCC) over the last 16 years, with Q3 2025 value amounting to -$2.1 million.

  • Immucell's Net Cash Flow fell 18502.42% to -$2.1 million in Q3 2025 from the same period last year, while for Sep 2025 it was $77565.0, marking a year-over-year decrease of 9573.62%. This contributed to the annual value of $2.8 million for FY2024, which is 15775.18% up from last year.
  • Immucell's Net Cash Flow amounted to -$2.1 million in Q3 2025, which was down 18502.42% from $1.4 million recorded in Q2 2025.
  • Over the past 5 years, Immucell's Net Cash Flow peaked at $3.9 million during Q2 2021, and registered a low of -$3.0 million during Q4 2022.
  • Moreover, its 5-year median value for Net Cash Flow was -$143287.0 (2021), whereas its average is -$161249.4.
  • As far as peak fluctuations go, Immucell's Net Cash Flow plummeted by 98180.64% in 2022, and later soared by 467289.88% in 2025.
  • Quarter analysis of 5 years shows Immucell's Net Cash Flow stood at -$310291.0 in 2021, then tumbled by 878.5% to -$3.0 million in 2022, then surged by 66.71% to -$1.0 million in 2023, then surged by 95.01% to -$50401.0 in 2024, then crashed by 4090.98% to -$2.1 million in 2025.
  • Its Net Cash Flow stands at -$2.1 million for Q3 2025, versus $1.4 million for Q2 2025 and $841139.0 for Q1 2025.